Treasury Inflation-Protected Securities offer a great risk-reward outlook, with PIMCO 15+ Year U.S. TIPS Index ...

Paycor HCM's new guidance indicates sustainable mid-teens recurring revenue growth. Click here to read why I've upgraded PYCR ...

NervGen's groundbreaking NVG-291 treatment for spinal cord injury is currently in trials with FDA Fast Track Designation.

CareDx has shown strong revenue growth and maintains a robust balance sheet. Read why CDNA stock is a prime candidate for my growth portfolio.

The current fears surrounding Google seem, in my opinion, overly inflated. Click here to read why GOOG stock remains a Buy.

We caution investors on Vistra, highlighting overvaluation despite growth and green initiatives. See why we suggest a hold on ...

Mastercard is a solid long-term investment with strong growth prospects, driven by its global reach and innovative business ...

T. Rowe Price Ultra Short-Term Bond ETF has a 5.3% yield with low volatility and alternative options for minimal ...

Over the course of the last two years, equity investors in the S&P 500 stocks have enjoyed a cumulative price only return of 57.3% ...

NNN REIT's dividend of 5.7% is well-supported by current earnings. Click here to read why growth potential is limited for NNN stock.

We recommend holding Adobe stock, with a potential buy opportunity at $350, citing strong cash flow and AI potential. Read an ...

Ares Capital's mix of floating rate debt principal outstanding has been steadily increasing since Q1 FY22. Read why ARCC ...